Barclays Raises Abivax (NASDAQ:ABVX) Price Target to $148.00

Abivax (NASDAQ:ABVX) had its target price upped by equities research analysts at Barclays from $142.00 to $148.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 28.50% from the company’s current price.

Several other analysts have also commented on ABVX. Wedbush assumed coverage on shares of Abivax in a research report on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price target for the company. Oppenheimer set a $131.00 price objective on shares of Abivax in a research report on Thursday, January 8th. Citigroup reissued a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, January 21st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $150.00 price target on shares of Abivax in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $137.15.

Abivax Stock Down 0.2%

Shares of ABVX traded down $0.25 during trading hours on Tuesday, hitting $115.18. The company had a trading volume of 249,792 shares, compared to its average volume of 1,187,742. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $9.12 billion, a PE ratio of -27.55 and a beta of 1.01. Abivax has a one year low of $4.77 and a one year high of $148.83. The company’s fifty day moving average price is $119.30 and its two-hundred day moving average price is $110.77.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($1.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.24) by $1.00. The company had revenue of $1.45 million for the quarter, compared to the consensus estimate of $1.80 million. As a group, equities analysts forecast that Abivax will post -2.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abivax

Several hedge funds have recently modified their holdings of the stock. UBS Group AG boosted its stake in Abivax by 2,561.0% in the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. purchased a new stake in Abivax during the 3rd quarter worth approximately $263,698,000. Morgan Stanley increased its stake in Abivax by 114.3% during the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after purchasing an additional 1,681,277 shares in the last quarter. Paradigm Biocapital Advisors LP purchased a new position in shares of Abivax in the third quarter worth $132,800,000. Finally, TCG Crossover Management LLC raised its holdings in shares of Abivax by 17.4% in the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after buying an additional 1,055,000 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.